Understanding Angiogenesis Inhibition with Cilengitide Trifluoroacetate
Angiogenesis, the formation of new blood vessels, is a fundamental process that supports tumor growth and metastasis. Cancer cells often hijack this process to ensure they receive adequate oxygen and nutrients, and to facilitate their spread throughout the body. Consequently, inhibiting angiogenesis has become a critical strategy in cancer therapy. Cilengitide Trifluoroacetate, a sophisticated pharmaceutical intermediate, plays a pivotal role in this area of research.
Cilengitide Trifluoroacetate is known for its potent ability to inhibit integrin receptors, specifically αvβ3 and αvβ5. These integrins are highly expressed on endothelial cells that form new blood vessels and are crucial for their adhesion and migration during angiogenesis. By blocking these integrins, Cilengitide disrupts the signaling pathways that drive the formation of new blood vessels within tumors. This mechanism directly impacts the tumor's ability to grow beyond a minimal size and to establish secondary tumors.
The scientific community widely uses Cilengitide Trifluoroacetate in both in vitro and in vivo studies to investigate the intricacies of angiogenesis and its role in various diseases, particularly cancer. Its efficacy in preclinical models has paved the way for its inclusion in clinical trials for several types of cancer, including gliomas and melanoma. The ability of this integrin inhibitor to block endothelial cell proliferation, migration, and survival is a testament to its potential in anti-cancer drug development.
For researchers focused on developing novel anti-cancer agents, sourcing high-quality Cilengitide Trifluoroacetate is paramount. As a reputable supplier in China, we are committed to providing compounds that meet stringent purity standards, ensuring the reliability and reproducibility of your experimental outcomes. Our goal is to empower your research into angiogenesis inhibition and the development of effective treatments. Purchase Cilengitide Trifluoroacetate to advance your critical work in this vital area of medical science.
Cilengitide Trifluoroacetate is known for its potent ability to inhibit integrin receptors, specifically αvβ3 and αvβ5. These integrins are highly expressed on endothelial cells that form new blood vessels and are crucial for their adhesion and migration during angiogenesis. By blocking these integrins, Cilengitide disrupts the signaling pathways that drive the formation of new blood vessels within tumors. This mechanism directly impacts the tumor's ability to grow beyond a minimal size and to establish secondary tumors.
The scientific community widely uses Cilengitide Trifluoroacetate in both in vitro and in vivo studies to investigate the intricacies of angiogenesis and its role in various diseases, particularly cancer. Its efficacy in preclinical models has paved the way for its inclusion in clinical trials for several types of cancer, including gliomas and melanoma. The ability of this integrin inhibitor to block endothelial cell proliferation, migration, and survival is a testament to its potential in anti-cancer drug development.
For researchers focused on developing novel anti-cancer agents, sourcing high-quality Cilengitide Trifluoroacetate is paramount. As a reputable supplier in China, we are committed to providing compounds that meet stringent purity standards, ensuring the reliability and reproducibility of your experimental outcomes. Our goal is to empower your research into angiogenesis inhibition and the development of effective treatments. Purchase Cilengitide Trifluoroacetate to advance your critical work in this vital area of medical science.
Perspectives & Insights
Core Pioneer 24
“Cilengitide Trifluoroacetate is known for its potent ability to inhibit integrin receptors, specifically αvβ3 and αvβ5.”
Silicon Explorer X
“These integrins are highly expressed on endothelial cells that form new blood vessels and are crucial for their adhesion and migration during angiogenesis.”
Quantum Catalyst AI
“By blocking these integrins, Cilengitide disrupts the signaling pathways that drive the formation of new blood vessels within tumors.”